0001062993-22-023796.txt : 20221213 0001062993-22-023796.hdr.sgml : 20221213 20221213164742 ACCESSION NUMBER: 0001062993-22-023796 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221209 FILED AS OF DATE: 20221213 DATE AS OF CHANGE: 20221213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sullivan Brian F. CENTRAL INDEX KEY: 0000940454 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38207 FILM NUMBER: 221460216 MAIL ADDRESS: STREET 1: 16305 36TH AVENUE N CITY: MINNEAPOLIS STATE: MN ZIP: 55446 FORMER NAME: FORMER CONFORMED NAME: SULLIVAN BRIAN F DATE OF NAME CHANGE: 19950307 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celcuity Inc. CENTRAL INDEX KEY: 0001603454 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 16305 36TH AVENUE N STREET 2: SUITE 100 CITY: MINNEAPOLIS STATE: MN ZIP: 55446 BUSINESS PHONE: 763-392-0767 MAIL ADDRESS: STREET 1: 16305 36TH AVENUE N STREET 2: SUITE 100 CITY: MINNEAPOLIS STATE: MN ZIP: 55446 FORMER COMPANY: FORMER CONFORMED NAME: Celcuity LLC DATE OF NAME CHANGE: 20140324 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2022-12-09 0001603454 Celcuity Inc. CELC 0000940454 Sullivan Brian F. 16305 36TH AVENUE NORTH SUITE 100 MINNEAPOLIS MN 55446 1 1 1 0 Chief Executive Officer Common Stock 2022-12-09 4 P 0 260869 5.75 A 3016643 D Stock Option (right to buy) 8.4000 2027-05-17 Common Stock 21500 21500 D Stock Option (right to buy) 5.50 2027-09-19 Common Stock 8220 8220 D Stock Option (right to buy) 5.50 2028-08-13 Common Stock 3769 3769 D Stock Option (right to buy) 5.50 2028-10-17 Common Stock 14675 14675 D Stock Option (right to buy) 5.50 2029-08-12 Common Stock 50000 50000 D Stock Option (right to buy) 5.50 2029-08-12 Common Stock 4985 4985 D Stock Option (right to buy) 5.9000 2030-08-12 Common Stock 20000 20000 D Stock Option (right to buy) 5.9000 2030-08-12 Common Stock 17281 17281 D Stock Option (right to buy) 5.50 2030-12-28 Common Stock 11081 11081 D Stock Option (right to buy) 5.50 2031-02-02 Common Stock 12859 12859 D Stock Option (right to buy) 5.50 2031-03-18 Common Stock 11889 11889 D Stock Option (right to buy) 5.50 2031-04-12 Common Stock 13509 13509 D Stock Option (right to buy) 5.50 2031-08-11 Common Stock 17000 17000 D Stock Option (right to buy) 5.50 2031-08-11 Common Stock 20000 20000 D Stock Option (right to buy) 5.50 2031-10-27 Common Stock 6569 6569 D Stock Option (Right to Buy) 5.50 2032-05-17 Common Stock 250000 250000 D Warrants (right to buy) 80.5000 2022-12-09 4 D 0 10434 0 D Series A Preferred Stock 10434 0 D Warrants (right to buy) 8.05 2022-12-09 4 A 0 104340 0 A 2027-12-09 Common Stock 104340 104340 D Common Stock (right to buy) 5.7500 2022-12-09 4 D 0 260869 0 D Common Stock 260869 0 D Acquired pursuant to a securities purchase agreement entered into with the Company on May 15, 2022. Fully vested. 12,500 shares vest on 8/12/20; the remaining 37,500 shares vest 1/36th per month thereafter. 5,000 shares vest on 8/12/21; the remaining 15,000 shares vest 1/36th per month thereafter. 2,770 shares vest on 12/29/21; the remaining 8,311 shares vest 1/36th per month thereafter. 3,214 shares vest on 2/2/22; the remaining 9,645 shares vest 1/36th per month thereafter. 2,972 shares vest on 3/18/22; the remaining 8,917 shares vest 1/36th per month thereafter. 3,377 shares vest on 4/12/22; the remaining 10,132 shares vest 1/36th per month thereafter. 5,000 shares vest on 8/11/22; the remaining 15,000 shares vest 1/36th per month thereafter. 1,642 shares vest on 10/27/22; the remaining 4,927 shares vest 1/36th per month thereafter. These shares vest in equal amounts over fourteen (14) months, beginning June 1, 2022. To comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, the security was initially reported as the right to acquire warrants to purchase 10,434 shares of Series A Preferred Stock at a price per share of $80.50 pursuant to a securities purchase agreement entered into with the Company on May 15, 2022. The Series A Preferred Stock underlying such securities was convertible into 104,340 shares of common stock. The transactions contemplated by the securities purchase agreement closed on the reported Transaction Date. Acquired pursuant to a securities purchase agreement entered into with the Company on May 15, 2022. The issued warrants on the transaction date provide the right to purchase 104,340 shares of common stock at a price per share of $8.05 instead of 10,434 shares of Series A Preferred Stock at a price per share of $80.50 as noted in Note 11 above due the occurrence of a specified event provided in the securities purchase agreement. To comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, the security was initially reported as the right to acquire shares of common stock pursuant to a securities purchase agreement entered into with the Company on May 15, 2022. The transactions contemplated by the securities purchase agreement closed on the reported Transaction Date. /s/ Eric O. Madson as Attorney-in-Fact for Brian F. Sullivan pursuant to Power of Attorney previously filed. 2022-12-13